ARID1A and cancer: Furthermore, Yokoyama et al. reported no differences regarding overall mortality between ARID1A+ and ARID1A− patients; yet, they described a significant association between disease free survival and ARID1A status, but only in TNM stage III-IV cancer patients [35].